Skip to content

US · GMED · MEDICAL - DEVICES

Globus Medical, Inc. (GMED) intrinsic value and stock valuation

$66.89as of 2026-11-21 · Mkt cap 11.11B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Globus Medical, Inc. DCF and intrinsic value

InvestorsCraft values GMED with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from GMED’s statements →

Globus Medical, Inc. Graham Number

Graham Number: $55.05d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Audubon, PA 19403-5214 globusmedical.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.94B+30.1% 5y CAGRd
20112025
Net income
$537.9M+39.4% 5y CAGRd
20112025
Free cash flow
$588.8M+34.2% 5y CAGRd
20112025
Total equity
$4.57B+24.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.94B$2.52B$1.57B$1.02B$958.1M
Operating income$479.8M$166M$133.1M$228M$172M
Net income$537.9M$103M$122.9M$190.2M$149.2M
EPSd$3.92M$747K$1.07M$1.85M$1.44M
Operating cash flow$753.5M$520.6M$243.5M$178.5M$276.3M
Capital expenditure-$-164.68M-$-115.43M-$-78.27M-$-74.05M-$-56.9M
Free cash flow$588.8M$405.2M$165.2M$104.4M$219.4M
Total assets$5.3B$5.25B$5.09B$2.08B$1.96B
Total debt$118.7M$537.2M$520.4M$6.01M$0.00
Net debt-$-407.5M-$-247.25M$53.1M-$-144.46M-$-193.07M
Total equity$4.57B$4.18B$4B$1.85B$1.74B
Cash and short-term investments$557.2M$890.1M$517.8M$446.1M$443.5M
Income statement
20252024202320222021
Revenue$2.94B$2.52B$1.57B$1.02B$958.1M
Cost of revenue$957.8M$1.04B$548.2M$263.7M$239.2M
Gross profit$1.98B$1.48B$1.02B$759.1M$718.9M
Research and development expenses$185M$163.8M$124M$73M$97.4M
Selling, general and administrative expenses$1.32B$981.1M$643.4M$432.1M$408.2M
Other expenses$0.00$173.1M$119.7M$26M$41.4M
Operating expenses$1.5B$1.32B$887.2M$531.2M$546.9M
Cost and expenses$2.46B$2.35B$1.44B$794.9M$786.2M
Interest income$7.14M$0.00$20.1M$14.2M$9.3M
Interest expense$0.00$4.19M$0.00$0.00$0.00
Depreciation and amortization$120M$254M$144.7M$68.3M$69.9M
Ebitda$729.9M$473.7M$346.6M$304.5M$264.7M
Operating income$479.8M$166M$133.1M$228M$172M
Total other income/expenses, net$130.1M-$-45.27M$32.3M$15.1M$8.45M
Income before tax$609.9M$120.7M$165.4M$243M$180.4M
Income tax expense$72M$17.7M$42.5M$52.9M$31.2M
Net income$537.9M$103M$122.9M$190.2M$149.2M
Weighted average shares outstanding$135.2M$135.7M$113.1M$100.5M$100.7M
Weighted average diluted shares outstanding$137.2M$137.9M$114.6M$102.6M$103.6M
Balance sheet
20252024202320222021
Cash and short-term investments$557.2M$890.1M$517.8M$446.1M$443.5M
Net receivables$743.7M$578.3M$504.9M$217.3M$165.7M
Inventory$759.3M$659.2M$848.1M$299M$237M
Total current assets$2.13B$2.18B$1.92B$983.3M$864.5M
Property, plant and equipment, net$628.2M$611.6M$646.9M$243.7M$221.1M
Goodwill and intangible assets$2.18B$2.23B$2.36B$261.1M$248.4M
Long-term investments$71.8M$66.1M$75.4M$495.9M$562.5M
Total non-current assets$3.18B$3.07B$3.17B$1.09B$1.09B
Total assets$5.3B$5.25B$5.09B$2.08B$1.96B
Accounts payable$98.9M$75.1M$56.7M$36.1M$22M
Short-term debt$14.7M$453.6M$12M$2.54M$0.00
Deferred revenue$27.7M$22.1M$18.4M$14.1M$12M
Total current liabilities$498.5M$855.9M$392.4M$159.2M$140.2M
Long-term debt$103.9M$83.6M$508.4M$3.48M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$231M$218.5M$695.8M$70.6M$75.7M
Capital lease obligations$14.7M$93.8M$103M$6.01M$0.00
Total liabilities$729.5M$1.07B$1.09B$229.8M$215.9M
Common stock$140K$140K$140K$100K$100K
Retained earnings$1.39B$1.15B$1.14B$1.24B$1.19B
Accumulated other comprehensive income (loss)$15.4M-$-6.86M-$-10.19M-$-24.63M-$-6.77M
Total equity$4.57B$4.18B$4B$1.85B$1.74B
Total investments$102.9M$171.8M$125.9M$791.4M$812.9M
Total debt$118.7M$537.2M$520.4M$6.01M$0.00
Net debt-$-407.5M-$-247.25M$53.1M-$-144.46M-$-193.07M
Cash flow statement
20252024202320222021
Net income$537.9M$103M$122.9M$190.2M$149.2M
Depreciation and amortization$276.8M$254M$144.7M$68.3M$69.9M
Stock-based compensation$49.8M$54.2M$52.7M$32.8M$30.6M
Change in working capital-$-82.71M-$-97.55M-$-116.6M-$-105.26M-$-17.25M
Accounts receivable-$-52.18M-$-78.06M-$-49.91M-$-50.84M-$-25.89M
Inventory-$-17.6M-$-29.86M-$-70.33M-$-61.74M-$-11.97M
Accounts payable$8.49M$17.7M-$-14.22M$14.4M$3.68M
Net cash provided by operating activities$753.5M$520.6M$243.5M$178.5M$276.3M
Investments in property, plant and equipment-$-164.68M-$-115.43M-$-78.27M-$-74.05M-$-56.9M
Acquisitions, net$13.5M-$-17.64M-$-296.03M-$-31.43M-$-34.49M
Net cash used for investing activities-$-355.01M-$-176.05M$303M-$-110.36M-$-375.94M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-300.45M-$-85.79M-$-225.56M-$-144.49M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-679.16M-$-27.7M-$-231.82M-$-109.96M$54.2M
Net change in cash-$-258.28M$317.2M$316.8M-$-42.6M-$-46.33M
Cash at end of period$526.2M$784.4M$467.3M$150.5M$193.1M
Operating cash flow$753.5M$520.6M$243.5M$178.5M$276.3M
Capital expenditure-$-164.68M-$-115.43M-$-78.27M-$-74.05M-$-56.9M
Free cash flow$588.8M$405.2M$165.2M$104.4M$219.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Globus Medical, Inc.

        Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

        CEO
        Keith W. Pfeil
        Employees
        6K
        Beta
        0.95

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Globus Medical, Inc. (GMED)?

        Globus Medical, Inc. (GMED) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GMED undervalued?

        GMED trades at a price of $66.89 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.